{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:09:56Z","timestamp":1793956196170,"version":"4.8.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA251138, R01 CA242020, and R01 CA283364"],"award-info":[{"award-number":["R01 CA251138, R01 CA242020, and R01 CA283364"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA254838-01"],"award-info":[{"award-number":["P50 CA254838-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL128239"],"award-info":[{"award-number":["R01 HL128239"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41375-025-02515-8","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T18:30:32Z","timestamp":1737743432000},"page":"765-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Philipovskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grerk","family":"Sutamtewagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Keiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Bhagwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6008-9630","authenticated-orcid":false,"given":"Joseph","family":"Rager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Heiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunhee","family":"Ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Jen","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"2515_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1182\/blood.2019004260","volume":"138","author":"S Chen","year":"2021","unstructured":"Chen S, Benbarche S, Abdel-Wahab O. Splicing factor mutations in hematologic malignancies. Blood. 2021;138:599\u2013612.","journal-title":"Blood"},{"key":"2515_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ajh.26757","volume":"98","author":"M Stahl","year":"2023","unstructured":"Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, et al. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. Am J Hematol. 2023;98:79\u201389.","journal-title":"Am J Hematol"},{"key":"2515_CR3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367\u201376.","journal-title":"Blood"},{"key":"2515_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm.4097","volume":"22","author":"SC Lee","year":"2016","unstructured":"Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016;22:672\u20138.","journal-title":"Nat Med"},{"key":"2515_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccell.2018.12.013","volume":"35","author":"S Yin","year":"2019","unstructured":"Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, et al. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell. 2019;35:283\u201396.e285.","journal-title":"Cancer Cell"},{"key":"2515_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.gendis.2019.06.002","volume":"6","author":"F Zhu","year":"2019","unstructured":"Zhu F, Rui L. PRMT5 in gene regulation and hematologic malignancies. Genes Dis. 2019;6:247\u201357.","journal-title":"Genes Dis"},{"key":"2515_CR7","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","volume":"24","author":"PJ Hamard","year":"2018","unstructured":"Hamard PJ, Santiago GE, Liu F, Karl DL, Martinez C, Man N, et al. PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes. Cell Rep. 2018;24:2643\u201357.","journal-title":"Cell Rep"},{"key":"2515_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2019.07.003","volume":"36","author":"JY Fong","year":"2019","unstructured":"Fong JY, Pignata L, Goy PA, Kawabata KC, Lee SC, Koh CM, et al. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell. 2019;36:194\u2013209.e199.","journal-title":"Cancer Cell"},{"key":"2515_CR9","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1182\/blood-2021-150938","volume":"138","author":"MR Patel","year":"2021","unstructured":"Patel MR, Monga V, Jauhari S, Stevens D, Masarova L, McKean M, et al. A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies. Blood. 2021;138:2609.","journal-title":"Blood"},{"key":"2515_CR10","doi-asserted-by":"publisher","first-page":"P039","DOI":"10.1158\/1535-7163.TARG-21-P039","volume":"20","author":"M McKean","year":"2021","unstructured":"McKean M, Patel MR, Wesolowski R, Ferrarotto R, Stein EM, Shoushtari AN, et al. Abstract P039: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with advanced solid tumors and lymphoma. Mol Cancer Ther. 2021;20:P039\u2013P039.","journal-title":"Mol Cancer Ther"},{"key":"2515_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"2515_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2515_CR13","doi-asserted-by":"publisher","first-page":"17960","DOI":"10.1073\/pnas.1209814109","volume":"109","author":"S Antonysamy","year":"2012","unstructured":"Antonysamy S, Bonday Z, Campbell RM, Doyle B, Druzina Z, Gheyi T, et al. Crystal structure of the human PRMT5:MEP50 complex. Proc Natl Acad Sci USA. 2012;109(:17960\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2515_CR14","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom LD, Aranda R, Waters L, Moya K, Bowcut V, Vegar L, et al. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. Cancer Discov. 2023;13:2412\u201331.","journal-title":"Cancer Discov"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02515-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02515-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T16:09:14Z","timestamp":1741104554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02515-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2515"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02515-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ATK had a consultancy with GSK, CTI Biopharma, Imago Biosciences, received honoraria from Incyte, MorphoSys, BMS, received travel support from Abbvie and MorphoSys, and participated on a Data Safety Monitoring Board or Advisory Board for Incyte. DAS had a consultancy with Abbvie, Gilead, Agios, Celyad, Foghorn, Incyte, Intellisphere, Kite, Magenta, Novartis, Affimed, Molecular Partners, PGEN Therapeutics, Takeda, and Zentalis. DAS served on the advisory board for Syros, Shattuck Labs, Jasper Therapeutics, Dark Blue Therapeutics, BMS, Syndax, Servier, Rigel Pharmaceuticals, AvenCell, Kite, Magenta, Novartis, Astellas, BlueBird Bio, Intellia, BMS, and Nkarta. DAS received research funding from Jazz Pharmaceuticals. MP had a consultancy with received honoraria from ION Pharma, Jansen Oncology, Olema Pharmaceuticals, Daiichi Sankyo, Kura Oncology, Accutar Biotech, and Nurix. AP received research funding from Monte Rosa Therapeutics, Frontier Med, Valerio, Abbvie, Immuneering, and Arvinas. LM participated on the advisory board for MorphoSys. GK received honoraria from Astellas and research funding from Prelude, Sumitomo Pharam, Schrodinger, Cyteir, and Abbvie. AV is a current equity holder in Stelexis, Clinstreet, and Bioconvergent health. AV received research funding from Prelude, BMS, Curis, and Halia. AV is a member of the board of directors or advisory committee of Stelexis, Curis and Calico. NB, MW, JR, AM, DH, SR, and WJH are current employees and equity holders of Prelude Therapeutics. OA-W is a founder and scientific advisor of Codify Therapeutics, holds equity in this company, and receives research funding from this company. OA-W has served as a consultant for Foundation Medicine Inc., Merck, Prelude Therapeutics, Amphista Therapeutics, MagnetBio, and Janssen, and is on the Scientific Advisory Board of Envisagenics Inc., Harmonic Discovery Inc., and Pfizer Boulder; OA-W has received prior research funding from H3B Biomedicine, Nurix Therapeutics, Minovia Therapeutics, and LOXO Oncology unrelated to the current manuscript. EMS received research funding from Bayer; was a consultant for Amgen, AbbVie, Seattle Genetics, and Biotheryx; served as a consultant and received research funding from Syndax; was a member of the Board of Directors or advisory committee for PTC Therapeutics and Syros; served as a consultant and was member of the Board of Directors or advisory committee for Astellas Pharmaceutical, Agios Pharmaceuticals, and Genentech; served as a consultant, received research funding, and was a member of the Board of Directors or advisory committee for Daiichi-Sankyo, Celgene Pharmaceuticals, and Novartis; and is a current equity holder in privately held Auron Therapeutics. All other authors have no conflicts of interest to declare. All conflicts of interest declared are unrelated to the content of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the review boards at the participating institutions. The names of these boards can be found in Supplementary Table 9. All patients provided written informed consent prior to enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}